Antacids, PPIs & Acid Reducers

Dried Aluminium Hydroxide (250mg), Magnesium Hydroxide (250mg), and Activated Dimethicone (50mg) Tablets and Suspension is a classic balanced antacid and antiflatulent on the WHO Model List of Essential Medicines. Aluminium hydroxide provides slow, prolonged acid neutralization (constipating), while magnesium hydroxide acts rapidly (laxative), providing a well-balanced bowel action. Dimethicone defoams gas bubbles, relieving gastric fullness and flatulence. Indicated for symptomatic relief of heartburn, acid indigestion, hyperacidity, and peptic ulcer symptoms.

Famotidine Tablets (20mg, 40mg) is a potent, highly selective competitive histamine H2-receptor antagonist on the WHO Model List of Essential Medicines. It is approximately 8 times more potent than ranitidine and 30 times more potent than cimetidine on a weight basis, without binding to hepatic cytochrome P450 enzymes or displaying antiandrogenic activity. Indicated for short-term treatment of active duodenal ulcer, active benign gastric ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions.

Famotidine Tablets (20mg, 40mg) is a potent, highly selective competitive histamine H2-receptor antagonist on the WHO Model List of Essential Medicines. It is approximately 8 times more potent than ranitidine and 30 times more potent than cimetidine on a weight basis, without binding to hepatic cytochrome P450 enzymes or displaying antiandrogenic activity. Indicated for short-term treatment of active duodenal ulcer, active benign gastric ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions.

Dried Aluminium Hydroxide (250mg), Magnesium Hydroxide (250mg), and Activated Dimethicone (50mg) Tablets and Suspension is a classic balanced antacid and antiflatulent on the WHO Model List of Essential Medicines. Aluminium hydroxide provides slow, prolonged acid neutralization (constipating), while magnesium hydroxide acts rapidly (laxative), providing a well-balanced bowel action. Dimethicone defoams gas bubbles, relieving gastric fullness and flatulence. Indicated for symptomatic relief of heartburn, acid indigestion, hyperacidity, and peptic ulcer symptoms.

Pantoprazole Gastro-Resistant Tablets (20mg, 40mg) is an oral substituted benzimidazole proton pump inhibitor on the WHO Model List of Essential Medicines. It covalently binds to the H+/K+-ATPase system at cysteine 813 and 822 on parietal cells, suppressing both basal and stimulated hydrochloric acid secretion for over 24 hours. Indicated for the treatment of duodenal ulcers, gastric ulcers, erosive esophagitis, gastroesophageal reflux disease (GERD), and pathological hypersecretory conditions including Zollinger-Ellison syndrome.

Pantoprazole for Injection (40mg vial) is an intravenous proton pump inhibitor on the WHO Model List of Essential Medicines. It irreversibly binds to H+/K+-ATPase proton pumps on parietal cells, achieving profound, immediate acid suppression. Indicated for short-term IV treatment of acute peptic ulcer bleeding, prevention of rebleeding following endoscopic hemostasis, severe erosive esophagitis in patients unable to take oral medications, and Zollinger-Ellison syndrome / hypersecretory states.

Rabeprazole Gastro-Resistant Tablets (20mg) is a second-generation proton pump inhibitor on the WHO Model List of Essential Medicines. It binds to gastric H+/K+-ATPase with high potency and dissociates more rapidly than first-generation PPIs, producing faster acid inhibition within hours of the first dose. Indicated for acute duodenal and gastric ulcers, gastroesophageal reflux disease (GERD), erosive esophagitis, and Zollinger-Ellison syndrome.

Ranitidine Injection (25mg/ml) is an intravenous histamine H2-receptor antagonist on the WHO Model List of Essential Medicines. It competitively and reversibly binds to histamine H2 receptors on gastric parietal cells, suppressing basal, nocturnal, and secretagogue-stimulated gastric acid and pepsin secretion. Indicated for hospital treatment of pathological hypersecretory states, active peptic ulcer hemorrhage, stress ulcer prophylaxis in critically ill patients, and prevention of acid aspiration during anesthesia.

Ranitidine Tablets (150mg, 300mg) and Syrup (75mg/5ml) is a selective, competitive histamine H2-receptor antagonist on the WHO Model List of Essential Medicines. It suppresses basal and nocturnal gastric acid secretion by over 70% and diminishes acid response to food and pentagastrin. Indicated for short-term treatment and maintenance of active duodenal ulcers, benign gastric ulcers, GERD, acid indigestion, and Zollinger-Ellison syndrome.

Ranitidine Tablets (150mg, 300mg) and Syrup (75mg/5ml) is a selective, competitive histamine H2-receptor antagonist on the WHO Model List of Essential Medicines. It suppresses basal and nocturnal gastric acid secretion by over 70% and diminishes acid response to food and pentagastrin. Indicated for short-term treatment and maintenance of active duodenal ulcers, benign gastric ulcers, GERD, acid indigestion, and Zollinger-Ellison syndrome.

Oxetacaine, Aluminium Hydroxide, and Magnesium Hydroxide Suspension is an anesthetic antacid combination. Aluminium and magnesium hydroxides provide balanced, nonsystemic neutralization of gastric hydrochloric acid, raising gastric pH and inhibiting peptic activity without causing rebound hypersecretion. Oxetacaine is a potent, non-irritating surface anesthetic that retains local anesthetic efficacy in strongly acidic environments (pH 1-2), producing rapid and long-lasting relief from acute burning ulcer and esophagitis pain. Indicated for severe acute gastritis, esophagitis, heartburn, and peptic ulcer pain.

Sucralfate Suspension (500mg/5ml) is an oral basic aluminum salt of sucrose octasulfate on the WHO Model List of Essential Medicines. Under acidic conditions (pH < 4), it polymerizes into an insoluble, polyanionic gel that adheres tenaciously to ulcerated mucosal tissue, protecting the ulcer crater from gastric acid, pepsin, and bile acids while stimulating endogenous prostaglandin synthesis and epidermal growth factor. Indicated for active duodenal ulcers, gastric ulcers, stress ulcer prophylaxis, and reflux esophagitis.

Omeprazole Gastro-Resistant Capsules (20mg) is a prototypical proton pump inhibitor on the WHO Model List of Essential Medicines. It enters parietal cell canaliculi as a prodrug where acidic pH converts it to a tetracyclic sulfenamide that permanently inactivates H+/K+-ATPase pumps. Indicated for duodenal ulcers, benign gastric ulcers, reflux esophagitis, maintenance therapy of healed erosive esophagitis, and H. pylori eradication (as part of triple therapy).

Lansoprazole Gastro-Resistant Capsules (15mg) is a substituted benzimidazole proton pump inhibitor on the WHO Model List of Essential Medicines. It suppresses both basal and stimulated gastric acid secretion by blocking H+/K+-ATPase on gastric parietal cells. Indicated for short-term and maintenance treatment of duodenal and benign gastric ulcers, gastroesophageal reflux disease (GERD), erosive esophagitis, and NSAID-induced gastric ulcer prophylaxis.

Liquid Paraffin (3.75ml) and Milk of Magnesia (11.25ml per 15ml) Suspension is a dual-mechanism emollient and osmotic laxative. Liquid paraffin is a mineral oil that coats fecal matter and retards water absorption, softening the stool and facilitating effortless expulsion. Milk of Magnesia draws water into the intestinal lumen via osmotic pressure, stimulating peristalsis. Indicated for constipation, painful defecation associated with piles, anal fissures, hernia, and post-operative recovery where straining must be avoided.

Magaldrate (400mg/540mg) and Simethicone (20mg/50mg, with or without Oxetacaine 10mg) Oral Suspension is a balanced antacid, antiflatulent, and mucosal anesthetic formulation. Magaldrate (hydroxymagnesium aluminate complex) reacts rapidly with gastric acid to buffer intragastric pH to the ideal 3.0-5.0 range, neutralizing acid without causing acid rebound. Simethicone breaks mucosal gas bubbles to relieve bloating. Oxetacaine (when present) provides prompt topical anesthesia on inflamed gastric and esophageal mucosa. Indicated for hyperacidity, heartburn, reflux esophagitis, gastritis, and peptic ulcer pain with flatulence.

Sucralfate (1g) and Oxetacaine (10mg) Suspension (per 10ml) combines a cytoprotective mucosal adherent with a potent local anesthetic. In the presence of gastric acid, sucralfate polymerizes into a viscous paste that selectively binds to positively charged proteinaceous exudates on ulcer craters, forming a protective physical barrier against acid, pepsin, and bile salts. Oxetacaine provides surface anesthesia to gastric and esophageal mucosa even in strongly acidic conditions (pH 1-2), delivering rapid relief from intense burning pain. Indicated for active gastric ulcers, duodenal ulcers, severe erosive esophagitis, and acute gastritis with severe epigastric pain.

Jan Pudina Soft Gel Capsules (Peppermint Oil / Menthol formulation) is a natural herbal carminative and antispasmodic on the PMBI formulary. Menthol, the active terpene of peppermint oil (Mentha piperita), selectively blocks voltage-gated L-type calcium channels on gastrointestinal smooth muscle cells, exerting direct smooth muscle relaxation and spasmolysis on the stomach and colonic wall. It relaxes the lower esophageal sphincter to facilitate gas evacuation and acts as a mild choleretic. Indicated for relief of gas bloating, indigestion, flatulence, abdominal distension, and irritable bowel syndrome (IBS) cramping.

Magaldrate (400mg/540mg) and Simethicone (20mg/50mg, with or without Oxetacaine 10mg) Oral Suspension is a balanced antacid, antiflatulent, and mucosal anesthetic formulation. Magaldrate (hydroxymagnesium aluminate complex) reacts rapidly with gastric acid to buffer intragastric pH to the ideal 3.0-5.0 range, neutralizing acid without causing acid rebound. Simethicone breaks mucosal gas bubbles to relieve bloating. Oxetacaine (when present) provides prompt topical anesthesia on inflamed gastric and esophageal mucosa. Indicated for hyperacidity, heartburn, reflux esophagitis, gastritis, and peptic ulcer pain with flatulence.

Ranitidine Tablets (150mg, 300mg) and Syrup (75mg/5ml) is a selective, competitive histamine H2-receptor antagonist on the WHO Model List of Essential Medicines. It suppresses basal and nocturnal gastric acid secretion by over 70% and diminishes acid response to food and pentagastrin. Indicated for short-term treatment and maintenance of active duodenal ulcers, benign gastric ulcers, GERD, acid indigestion, and Zollinger-Ellison syndrome.

Sodium Bicarbonate Tablets (500mg, 1000mg) is an oral systemic alkalizing agent and fast-acting antacid on the WHO Model List of Essential Medicines. It reacts instantaneously with hydrochloric acid in the stomach to produce sodium chloride, carbon dioxide, and water, rapidly neutralizing acidity and elevating gastric pH. Systemically, absorbed bicarbonate ions increase blood and urinary pH. Indicated for rapid relief of acute heartburn/acid indigestion, metabolic acidosis management, and urinary alkalinization (in uric acid stones, cystinuria, or methotrexate excretion).

Sodium Bicarbonate Tablets (500mg, 1000mg) is an oral systemic alkalizing agent and fast-acting antacid on the WHO Model List of Essential Medicines. It reacts instantaneously with hydrochloric acid in the stomach to produce sodium chloride, carbon dioxide, and water, rapidly neutralizing acidity and elevating gastric pH. Systemically, absorbed bicarbonate ions increase blood and urinary pH. Indicated for rapid relief of acute heartburn/acid indigestion, metabolic acidosis management, and urinary alkalinization (in uric acid stones, cystinuria, or methotrexate excretion).

Omeprazole Gastro-Resistant Capsules (20mg) is a prototypical proton pump inhibitor on the WHO Model List of Essential Medicines. It enters parietal cell canaliculi as a prodrug where acidic pH converts it to a tetracyclic sulfenamide that permanently inactivates H+/K+-ATPase pumps. Indicated for duodenal ulcers, benign gastric ulcers, reflux esophagitis, maintenance therapy of healed erosive esophagitis, and H. pylori eradication (as part of triple therapy).

Pantoprazole Gastro-Resistant Tablets (20mg, 40mg) is an oral substituted benzimidazole proton pump inhibitor on the WHO Model List of Essential Medicines. It covalently binds to the H+/K+-ATPase system at cysteine 813 and 822 on parietal cells, suppressing both basal and stimulated hydrochloric acid secretion for over 24 hours. Indicated for the treatment of duodenal ulcers, gastric ulcers, erosive esophagitis, gastroesophageal reflux disease (GERD), and pathological hypersecretory conditions including Zollinger-Ellison syndrome.

Omeprazole Gastro-Resistant Capsules (20mg) is a prototypical proton pump inhibitor on the WHO Model List of Essential Medicines. It enters parietal cell canaliculi as a prodrug where acidic pH converts it to a tetracyclic sulfenamide that permanently inactivates H+/K+-ATPase pumps. Indicated for duodenal ulcers, benign gastric ulcers, reflux esophagitis, maintenance therapy of healed erosive esophagitis, and H. pylori eradication (as part of triple therapy).

Ilaprazole Tablets (10mg) is a third-generation proton pump inhibitor with an extended plasma elimination half-life (~7-8 hours). It covalently inactivates H+/K+-ATPase pumps and delivers prolonged intragastric pH control, effectively preventing nocturnal acid breakthrough and accelerating peptic ulcer healing. Indicated for duodenal ulcers, gastric ulcers, erosive esophagitis, and refractory GERD.

Lansoprazole Gastro-Resistant Capsules (15mg) is a substituted benzimidazole proton pump inhibitor on the WHO Model List of Essential Medicines. It suppresses both basal and stimulated gastric acid secretion by blocking H+/K+-ATPase on gastric parietal cells. Indicated for short-term and maintenance treatment of duodenal and benign gastric ulcers, gastroesophageal reflux disease (GERD), erosive esophagitis, and NSAID-induced gastric ulcer prophylaxis.

Omeprazole (20mg) with Sodium Bicarbonate Powder for Oral Suspension is an immediate-release proton pump inhibitor formulation. Sodium bicarbonate neutralizes gastric acid instantly, elevating intragastric pH and protecting unprotected omeprazole from acid degradation during transit to the duodenum, allowing rapid absorption without enteric coating. Indicated for acute heartburn relief, active duodenal/gastric ulcers, GERD, and prevention of upper GI bleeding in critically ill patients.

Rebamipide Tablets (100mg) is an oral mucosal protective and cytoprotective antiulcer agent. It stimulates endogenous prostaglandin (PGE2 and PGI2) generation in gastric mucosa, promotes gastric mucus synthesis and blood flow, scavenges reactive oxygen species, and suppresses inflammatory cytokine expression. Indicated for gastric ulcers and improvement of gastric mucosal lesions (erosion, bleeding, redness, and edema) in acute gastritis and acute exacerbation of chronic gastritis.